Annonce • Jul 28
Waters Corporation Launches Xevo TQ Absolute XR IVD Mass Spectrometer Waters Corporation announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers. Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class, the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment, and hair toxicology for detecting drugs of abuse and documenting long-term exposure. Featuring the new StepWave XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System. This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components. This new MassTrak LC-MS/MS IVD System includes the ACQUITY UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers industry-leading sensitivity, enhanced robustness for complex sample matrices, and a user-friendly design that helps maximize laboratory uptime. Annonce • Jul 02
Waters Corporation to Report Q2, 2026 Results on Aug 04, 2026 Waters Corporation announced that they will report Q2, 2026 results on Aug 04, 2026 Annonce • Jun 09
Waters Corporation Launches BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns Waters Corporation had announced the launch of the BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution and speed while fitting into existing workflows. BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP-1 impurities and LNP components faster when speed matters, and with extraordinary resolution when certainty is required. BioResolve Peptide and GTxResolve Lipid Columns use specially designed surface chemistries and superficially porous particles to deliver precise RP separations with selectivity for two difficult sample types. Available in Phenyl-Hexyl+ and C18+ chemistries with 230 Å pore size particles, they are designed to support efficient mass transfer, consistent performance across U(H)PLC and HPLC systems, and reliable, batch-tested results from early-stage research through manufacturing. GLP-1 peptides are especially challenging to analyze because many impurities differ by just one atom, while others have no difference in atomic composition and vary only in how their atoms are arranged spatially. BioResolve Peptide Phenyl-Hexyl+ and C18+ Columns are built to resolve these difficult impurities, with specialized 300 mm formats available when maximum separation performance and deeper impurity characterization are required. For LNP and lipid workflows, the charged surface of GTxResolve Columns helps sharpen peaks for ionizable lipids by reducing tailing. Their larger pore size makes it easier for a wide range of lipid molecules to move through the column, improving peak shape and resolving challenging co-elutions. In addition, the superficially porous particle design speeds the movement of molecules through the stationary phase, shortening run times without reducing selectivity. GTxResolve Lipid RP Columns have demonstrated strong performance for lipid quantitation and impurity analysis, with reduced run times and excellent peak shape. The ability to tune separations for specific lipid components, combined with compatibility across multiple detector platforms (UV, MS, ELSD, and CAD), provides significant flexibility for characterization of diverse lipid species. Waters' BioResolve Peptide and GTxResolve Lipid Columns will be available globally beginning June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase. Annonce • Jun 04
Waters Corporation Announces FDA 510(k) Clearance Of BD BACTEC FXI Culture System Waters Corporation announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories. Clinical study data showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%, faster diagnostic workflows are critical in acute care settings. The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices. Designed for high-throughput microbiology labs, the BD BACTEC FXI Culture System fully automates vial loading, unloading, incubation, and detection alerts, with an automated loading capacity of up to 60 vials at a time, 50% more vials than the leading competitor. Available in 480- and 960-vial configurations, the BD BACTEC FXI Culture System delivers scalable efficiency while reducing manual intervention and increasing staff walk-away time. The BD BACTEC FXI Culture System was recently CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR) and licensed by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for availability in Europe and Japan. The BD BACTEC FXI Culture System and BD BACTEC Blood Culture Vials are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries. BD is a trademark of Becton, Dickinson and Company. Waters is a trademark of Waters Corporation or its affiliates. All other marks are the property of their respective owners. The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation. Becton, Dickinson and Company or one of its affiliates or subsidiaries remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. Annonce • May 06
Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026 Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion.
For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. Annonce • Apr 15
Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large Molecules Waters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026. Annonce • Apr 10
Waters Corporation, Annual General Meeting, May 21, 2026 Waters Corporation, Annual General Meeting, May 21, 2026. Annonce • Apr 08
Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay Waters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries. Annonce • Mar 10
Waters Corporation Launches ARES-G3 Rheometer Waters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order. Annonce • Feb 09
Waters Corporation Appoints Claire M. Fraser to Its Board of Directors Waters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo. Annonce • Jan 27
Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026 Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026 Annonce • Nov 12
Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower Software Waters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026. Annonce • Nov 05
Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025 Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20.
The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20. Annonce • Oct 01
Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025 Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025 Annonce • Jul 15
Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion. Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026.
Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts.
Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD. Annonce • May 23
Waters Corporation (NYSE:WAT) acquired Halo Labs. Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation.
Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025. Annonce • May 21
Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025.
Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025. Annonce • May 06
Waters Corporation Provides Earnings Guidance for the Second Quarter Ending June 28, 2025 and Full Year Ending December 31, 2025 Waters Corporation provided earnings guidance for the second quarter ending June 28, 2025 and full year ending December 31, 2025. For the second quarter, the company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, second quarter 2025 reported sales growth is expected in the range of +4.0% to +6.0%. GAAP earnings per diluted share is expected to be between $2.66 to $2.76.
For the year 2025, the company expects constant currency sales growth guidance to the range of +5.0% to +7.0%. Net of currency translation, the company is raising its full-year 2025 reported sales growth to the range of +4.0% to +6.0%. GAAP earnings per diluted share is expected to be between $11.88 to $12.18. Annonce • Apr 11
Waters Corporation, Annual General Meeting, May 22, 2025 Waters Corporation, Annual General Meeting, May 22, 2025. Annonce • Apr 01
Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC Waters Corporation announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, advancing the capabilities of the next-generation intelligent HPLC platform designed for development and Quality Control (QC) laboratories. The Alliance iS HPLC Platform has been purposefully designed to simplify laboratory workflows by reducing the risk of out-of-specification results and the need for troubleshooting. Default system parameters provide over threefold improvement in day-to-day reproducibility and reduce carryover by up to two orders of magnitude, compared to other systems on the market. Additionally, with MaxPeak Premier columns, the Alliance iS Bio HPLC System enhances out-of-the-box sensitivity by up to 80 times compared to traditional systems and columns. Waters now offers four configurations of the Alliance iS HPLC Platform to support routine quantitative analysis and expanded spectral analysis of small and large molecules in development and QC. All configurations are controlled by the compliance-ready Waters EmpowerTM Chromatography Data System, which enables laboratories to collect, manage, and report chromatography test results. The platform also supports connectivity with laboratory information management systems (LIMS) to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity. The Alliance iS HPLC Platform has earned the Accountability, Consistency, and Transparency (ACT) Ecolabels from My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. Notably, the product line was recognized for its sustainable manufacturing practices and innovative error-reducing design, underscoring the commitment of Waters to reducing the most significant environmental impacts. The Waters Alliance iS Bio HPLC System with PDA detection is available for order now. Annonce • Feb 13
Waters Corporation Provides Earnings Guidance for the First Quarter of 2025 and Full Year 2025 Waters Corporation provided earnings guidance for the first quarter of 2025 and full year 2025. For the quarter, the company expects constant currency sales growth to be in the range of +4.0% to +7.0%. Currency translation is expected to decrease first quarter sales growth by approximately 3.0%. The resulting first quarter 2025 reported sales growth is expected in the range of +1.0% to +4.0%.
For the full year, the company expects constant currency sales growth to be in the range of +4.5% to +7.0%. Currency translation is expected to decrease full-year sales growth by approximately 2.0%. The resulting full-year 2025 reported sales growth is expected in the range of +2.5% to +5.0%. Annonce • Nov 02
Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024 Waters Corporation raised earnings guidance for the full year of fiscal year ending December 31, 2024. The company is raising its full-year 2024 sales guidance, and now expects organic constant currency sales growth to be in the range of negative 0.9% to negative 0.3%. Currency translation is expected to decrease full-year sales growth by 1.2%. M&A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of negative 0.8% to negative 0.2%. GAAP earnings per diluted share to be in the range of $10.55 to $10.75. Annonce • Nov 01
Waters Corporation Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2024 Waters Corporation provided earnings guidance for the fourth quarter ending December 31, 2024. The company expects fourth quarter 2024 constant currency sales growth to be in the range of positive 5.0% to positive 7.0%. Currency translation is expected to decrease fourth quarter sales growth by 1.7%. The resulting fourth quarter 2024 reported sales growth is expected in the range of positive 3.3% to positive 5.3%. GAAP earnings per diluted share to be in the range of $3.72 to $3.92. Annonce • Oct 14
Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis Waters Corporation introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry analysis. When used together in a workflow, these bioseparations tools help accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, such as CRISPR sgRNA and mRNA therapeutics. Large molecule RNA (ribonucleic acid) therapeutics represent some of the most exciting and potentially life-saving developments in pharmaceuticals today. They include new and more effective vaccines for diseases like COVID-19, personalized cancer treatments, as well as emerging CRISPR RNA therapies that address challenging genetic conditions, such as sickle cell anemia. The Waters RNA analytical tools include:
Enzymes: Two novel enzymes, RapiZyme MC1 and RapiZyme Cusativin, are used in a simplified three-step protocol that provides complete LC-MS sequence coverage over traditional digestion methods enabling more confident characterization of RNA molecules. Reagents: IonHance HFIP, an LC-MS-grade reagent, is formulated to improve ionization and delivers increased spectral clarity and detection accuracy of RNA components. Software: New MAP Sequence application on the waters_connect software platform simplifies RNA LC-MS oligo mapping workflows to accelerate analysis and data processing time over manual techniques using spreadsheets. Used together within a workflow, the tools generate an LC-MS fingerprint to confirm product identity, purity, and efficacy. The tools improve sequence coverage, LC-MS spectral data quality, and data interpretation. Supported by the compliance-ready waters_connect software platform, these tools help transition LC and LC-MS-based digestion analysis from discovery and development to release and at-line process analytical testing. Waters RapiZyme RNAses and IonHance HFIP are now available. The new MAP Sequence App on waters_connect software will be available on October 18, 2024. Annonce • Oct 08
Waters Corporation Introduces TA Instruments Discovery Core Rheometer Waters Corporation introduced the TA Instruments Discovery Core Rheometer, a streamlined, modern rheometer designed for routine manufacturing quality control and assurance laboratories. The new analyzer can handle multiple material types such as battery slurries, printing inks, food, and personal care products and it features an easy-to-use touchscreen interface with self-guided training, methods, and applications for all levels of rheology users. The Discovery Core Rheometer expands the company's rheology portfolio, providing superior performance at an affordable price over commercial viscometers and other similarly appointed rheometers, delivering up to 2x lower torque sensitivity. The compact instrument requires half the bench space of comparable modular rheometers and owes its smaller size to the use of self-contained temperature control and electronics. The instrument comes equipped with the new RheoGuide Software user interface (UI), designed for immediate walk-up use. This UI provides self-guided training applications and pre-defined methods coupled with on-screen alerts and indicators for easier sample set-up, faster, real-time data analysis, and improved operator safety. The Discovery Core Rheometer shares methods and raw data file formats with other Discovery Hybrid Rheometers through TA Instruments TRIOS™ Software, enabling consistent measurements and data review from R&D to production. The Discovery Core Rheometer is orderable, with worldwide availability in First Quarter 2025. Annonce • Jul 23
Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs Waters Corporation announced the global release of the TA Instruments™ Rapid Screening- Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers. The TA Instruments RS-DSC is a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations specifically for antibody drugs and engineered proteins. The TA Instruments RS- DSC offers a more convenient and accurate solution to assess biological drug stability and quality by employing disposable, low sample volume microfluidic chips (MFCs) that enable up to 24 simultaneous measurements. This reduces or eliminates the need for sample dilution, repetitive instrument cleaning, and lowers contamination risk. Its unique design avoids the sensitivity challenges of DSF methods, enabling it to produce more accurate data on high-concentration samples. Additionally, the TA Instruments RS-DSC features automated software that provides rapid, effortless, precise, and in-depth insights about a sample's thermodynamic properties. The TA Instruments RS-DA is now available globally to all customers through the TA Instruments Division of Waters Corporation. Annonce • May 08
Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024 Waters Corporation provided earnings guidance for the second quarter and full year of 2024. For the second quarter, the company expects organic constant currency sales growth to be in the range of -6.0% to -4.0%. Currency translation is expected to decrease second quarter sales growth by approximately 2%. The resulting second quarter 2024 reported sales growth is expected in the range of -6.5% to -4.5%.For the year 2024, the company expects organic constant currency sales growth to be in the range of -0.5% to +1.5%. Currency translation is expected to decrease full-year sales growth by slightly less than 1%. The resulting full-year 2024 reported sales growth is expected in the range of 0.0% to +2.0%. Annonce • Apr 23
Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns Waters Corporation introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000A 3-micron (3 um) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak™? Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell & gene, mRNA and LNPs. SEC has emerged as an important platform analytical technique, but existing technologies require extensive column conditioning, consume large amounts of sample, and require lengthy run times to resolve impurities, making them an imperfect solution. Waters GTxResolve Premier SEC 1000Å 3 µm Columns address those challenges by providing higher sensitivity, resolution, and throughput by combining novel particle technology with low adsorption MaxPeak Premier HPS Technology. They make it possible for scientists to assess drug safety and efficacy more quickly and expedite the development of gene-based therapeutics and vaccines that are both more efficacious and accessible to patients globally. GTxResolve Premier SEC Columns are engineered to reduce problematic non-specific binding, minimize mobile phase method development challenges, and provide higher throughput separation efficiency. They offer up to 50% increases in resolution for components present within mRNA, LNPs, and viral vector samples. They offer low out-of-the-box secondary interactions, enabling robust multi-attribute platform methods and more than 2x improvements in sample consumption, run times, and sensitivity versus existing 5 and 10 µm HPLC columns. Waters GTxResolve Premier SEC 1000Å 3 µm Columns are now available globally, alongside Waters previously released GTxResolve Premier BEH SEC 450Å 2.5 µm Columns. These column technologies are quality control batch-tested with an industry-first use of both protein and nucleic acid test mixtures to ensure new levels of separation reproducibility. Annonce • Mar 30
Waters Corporation, Annual General Meeting, May 23, 2024 Waters Corporation, Annual General Meeting, May 23, 2024, at 09:00 US Eastern Standard Time. Agenda: To elect directors to serve for the ensuing year and until their successors are elected; to ratify the selection of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, by non-binding vote, executive compensation; to amend the company's certificate of incorporation to provide for exculpation of certain officers of the company as permitted by recent amendments to Delaware law; and to consider other matters. Annonce • Feb 06
Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024 Waters Corporation provided earnings guidance for the First Quarter and Full-Year 2024. For the quarter, the company expects organic constant currency sales growth to be in the range of -11% to -9%. Currency translation is expected to decrease first quarter sales growth by approximately 1%. The Wyatt transaction is expected to increase first quarter reported sales growth by 3.5%. The resulting first quarter 2024 reported sales growth is expected in the range of -8.5% to -6.5%.For the year, the company expects organic constant currency sales growth to be in the range of -0.5% to +1.5%. Currency translation is expected to decrease full-year sales growth by approximately 1%. M&A contribution from the Wyatt transaction covering the first four and a half months of the year is expected to increase full-year reported sales growth by 1.3%. The resulting full-year 2024 reported sales growth is expected in the range of 0% to +2%. Annonce • Oct 25
Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division Waters Corporation announced that Jonathan Pratt has decided to step down from his role as Senior Vice President of the Waters Division, to pursue an external opportunity. He will remain with Waters until October 27, 2023 to ensure a smooth transition. Christos (“Chris”) Ross, Senior Vice President of Global Operations, will serve as Interim Senior Vice President of the Waters Division effective immediately, until a permanent successor is named. Mr. Ross will continue as Senior Vice President of Global Operations and will maintain his existing responsibilities with the support of the Global Operations leadership team and the Executive Committee. As part of its normal process the Company has initiated a search to identify a permanent successor and will evaluate internal and external candidates. Annonce • Oct 20
Waters Corporation Launched OligoWorks SPE Workflow and Kits Waters Corporation announced the launch of OligoWorks SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments. The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies. OligoWorks SPE Kits also use an innovative, enzyme-enhanced, and detergent-free sample pretreatment that reduces washing steps and improves mass spectrometer compatibility, thus enabling direct injection LC-MS analysis and lower limits of quantitation. They can also be fully automated for improved productivity, or to simply help scientists gain back time by reducing manual steps and oversight. Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis. They complement Waters best-selling MaxPeak Premier Columns, ACQUITY Premier LC System and Arc Premier LC System, Andrew+ Pipetting Robot, and the class-leading sensitivity of the Waters Xevo TQ Absolute Mass Spectrometer. Annonce • Sep 21
Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis Waters Corporation introduced the DynaPro™ ZetaStar™ instrument from its Wyatt Technology™ portfolio for nanoparticle analysis. The new instrument simultaneously enables dynamic and static light scattering and dynamic and electrophoretic light scattering (DLS/SLS/ELS) measurements, all in one device. By combining multiple light scattering techniques and automatically assessing data quality and performing adaptive data capture, the ZetaStar instrument delivers both increased sensitivity and faster measurements to aid the precise development of complex biologics, using extremely low sample volumes. A unique flow cell design allows the ZetaStar instrument to be configured with an autosampler, significantly increasing laboratory efficiency and productivity with dozens of unattended measurements that can be run for several hours or even overnight. The instrument's ability to measure simultaneous DLS and ELS along with the adaptive data collection functionality, improves the speed of traditional ELS measurements by up to 10x. The simple design of the ZetaStar instrument features a walk-up touchscreen interface that allows scientists to collect five critical parameters in a single workflow: size, polydispersity, particle concentration, zeta potential, and turbidity, thus allowing extremely low sample volumes (down to 2 µL). These parameters are essential for characterizing the size and charge (zeta potential) of particles and macromolecules in a solution. The instrument implements a novel algorithm that removes potential user error and bias, leading to easier implementation and faster time to results. System uptime has also been improved with features that prevent the instrument from falling out of alignment, leading to a more efficient lab. Designed to support the expanding needs of biopharma formulation and development laboratories, the ZetaStar instrument helps scientists working in gene therapy, vaccines, mRNA, and proteins develop more stable therapies. It can also benefit R&D laboratories in material science investigating the colloidal stability of novel molecules like quantum dots or other metal nanoparticles used in semiconductor applications. Annonce • Aug 04
Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023 Waters Corporation provided earnings guidance for the third quarter and full year 2023. For the quarter, the company expects third quarter 2023 organic constant currency sales growth to decline in the range of -4% to -2%. Currency translation is expected to increase third quarter sales growth by approximately 1%. The Wyatt transaction is expected to increase third quarter reported sales growth by approximately 4%. The resulting third quarter 2023 reported sales growth is expected in the range of 1% to 3%. For the year, the company expects full-year 2023 organic constant currency sales growth in the range of 0.5% to 1.5%. Currency translation is expected to have minimal impact on full-year organic sales growth. The Wyatt transaction is expected to increase full-year reported sales growth by approximately 2.5%. The resulting full-year 2023 reported sales growth is expected in the range of 3% to 4%. Annonce • Aug 02
Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications Waters Corporation introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters™ XBridge™ Premier GTx BEH™ SEC columns doubles the speed of measuring the potency and safety of AAVs. Combining the columns with light scattering technologies from its Wyatt Technology portfolio deepens the level of information acquired from a single experiment and optimizes the manufacturing of these novel gene delivery vehicles. AAVs are modified viruses made in bioreactors by living cells and are the number one vehicle for carrying therapeutic genes into human cells. Waters scientists have developed a fast and efficient multi-attribute quantification methodiv of characterizing AAVs that features the following Waters products: ACQUITY™ Premier UPLC™ Systems or Arc™ Premier HPLC Systems; XBridge Premier GTx BEH SEC 450Å 2.5 µm columns; Arc Premier 2489 UV/Visible detector or 2998 photodiode array detector; Wyatt™ DAWN™ multi-angle light scattering detector; and Wyatt Optilab™ differential refractive index detector. XBridge Premier GTx BEH SEC columns are now available worldwide from Waters. Annonce • May 10
Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023 Waters Corporation provided earnings guidance for the second quarter of 2023 and fiscal year 2023. For the quarter, the company expects constant currency sales growth in the range of 1% to 3%. Currency translation is expected to decrease second quarter sales growth by approximately 1%. For the full year, the company expects full-year 2023 organic constant currency sales growth in the range of 3% to 5%. Currency translation is expected to have minimal impact on full-year organic sales growth. The Wyatt transaction is expected to increase full-year reported sales growth by approximately 2.5%. The resulting full-year 2023 reported sales growth is expected in the range of 5.5% to 7.5%. Annonce • Feb 16
Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023 Waters Corporation provided earnings guidance for the first quarter of 2023 and fiscal year 2023. For the quarter, the company expects constant currency sales growth in the range of 4% to 6%. Currency translation is expected to decrease first quarter sales growth by approximately 4%.For the full year, the company expects full-year 2023 organic constant currency sales growth in the range of 5% to 6.5%. Currency translation is expected to decrease full-year organic sales growth by approximately 1%. Annonce • Jan 26
Waters Corporation Announces Waters_Connect™ System Monitoring Waters Corporation announced waters_connect™ System Monitoring, a new Software-as-a-Service (SaaS) application that enables laboratory managers and analysts to monitor the real-time status of any chromatography instruments, regardless of the manufacturer, running on Waters™ Empower™ Software The waters_connect System Monitoring app is the only cloud-native software application that enables real-time monitoring of all chromatography instruments controlled by Waters Empower software. (Photo: Business Wire) The waters_connect System Monitoring application was developed especially for high-volume quality assurance/quality control (QA/QC) laboratories. It can reduce the turnaround time of product release samples and facilitate the planning and progress of critical analyses via live, at-a-glance dashboard views of the operational status of chromatography instruments. The cloud-native application also helps lab managers utilize capital resources better by providing an understanding of instrument history and usage levels and improve the productivity of their teams. The waters_connect System Monitoring application is available immediately in Europe and North America. Annonce • Dec 15
Waters Corporation Announces Executive Changes Waters Corporation announced that On December 13, 2022, at a meeting of the Board, the Board appointed Dan Brennan to the Audit Committee and Mark Vergnano to the Nominating and Corporate Governance Committee, effective immediately. The information reported under Item 5.02 of the November 23, 2022 Form 8-K is hereby incorporated by reference. Annonce • Nov 24
Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors Waters Corporation announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. The addition of Mr. Brennan and Mr. Vergnano is part of the Board’s ongoing refreshment process. With these appointments, the Board will expand to nine members, eight of whom are independent and five of whom have been appointed in the last five years. In his current role as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, Mr. Brennan is responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development. Prior to that, he was the company’s Senior Vice President and Corporate Controller and held other roles of increasing responsibility within finance. He holds a B.S. in Finance and Investments and an M.B. A from Babson College and is also a certified public accountant. Mr. Vergnano currently serves as a Partner at Sea Shell Partners. He previously served as the Chairman, President and Chief Executive Officer of The Chemours Company. Prior to that, he held roles of increasing responsibility at E.I. Dupont De Nemours & Company, culminating in his role as Executive Vice President. Mr. Vergnano received a B.S. from the University of Connecticut and an M.B.A. from Virginia Commonwealth University. He currently serves on the Board of Johnson Controls International. Annonce • Nov 23
Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to Waters_Connect Informatics Platform Waters Corporation announced a new Per-and Polyfluoroalkyl Substances (PFAS) quantitation workflow enabled by enhancements to its waters_connect™ for quantitation software. Through a combination of Waters™ ultra-sensitive instrumentation, sample prep chemistries and software, the end-to-end workflow simplifies and automates the measurement of PFAS in food, soil, air, and water at parts-per-quadrillion levels that meet and exceed regulatory detection limits. A key component of the waters_connect for quantitation software is the MS Quan™ app which includes an Exception Focused Review feature allowing users to implement tailored rulesets to focus the review process on only those results that fall outside specified targets, cutting data review time by up to 50%. In addition to the waters_connect for quantitation software, the Waters PFAS quantitation workflow solution consists of everything needed for laboratories to measure PFAS accurately and reproducibly in a variety of sample matrices. Products include Waters’ ultra-sensitive liquid chromatography and mass spectrometry instruments, separation columns and sample preparation cartridges. The Waters PFAS quantitation workflow solution and updated waters_connect for quantitation software are now available worldwide from Waters. Annonce • Nov 02
Waters Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Waters Corporation provided earnings guidance for the fourth quarter and full year of 2022. For the year, the company expects constant currency sales growth in the range of 11.5% to 12%. Currency translation is expected to decrease full-year sales growth by approximately 6%. Projected GAAP earnings per diluted share to be $3.64 - $3.74.For the quarter, the company expects constant currency sales growth in the range of 6% to 8%. Currency translation is expected to decrease fourth quarter sales growth by approximately 8%. Projected GAAP earnings per diluted share to be $11.58 - $11.68 . Annonce • Oct 12
Waters Automates Solid Phase Extraction of Biological, Food and Environmental Samples with Andrew+ Pipetting Robot Waters Corporation introduced Extraction+ Connected Device, a new software-controlled product for the Waters™ Andrew+™ Pipetting Robot that automates the preparation of biological, food, forensics and environmental samples by solid phase extraction (SPE). The Extraction+ Connected Device eliminates the need to manually pipette and extract samples with a hands-free, automated approach to SPE. It can save scientists up to four hours of bench time for each sample set and reduce the risk of user-to-user variability. The Extraction+ Connected Device is one of several “connected devices” for the Andrew+ Pipetting Robot, which are controlled using Waters’ OneLab Software. With a simple and intuitive user interface, OneLab Software makes it easy for designing and executing automated sample preparation protocols such as pipetting, shaking, cooling and heating, and purifying genomic, plasmid and mitochondrial DNA samples. The Extraction+ Connected Device consists of a new smart pump, a manifold for holding 1cc, 3cc and 6cc cartridges or elution plates, and software for creating and controlling pressure gradients during SPE cleanup procedures. The Extraction+ Connected Device is now available from Waters worldwide. Annonce • Sep 30
Waters Extends Capabilities of Flagship Ta Instruments Rheometer for Efficient and Repeatable Powder Analysis Waters Corporation introduced new, innovative powder rheology tooling and software for its TA Instruments™ HR Rheometers allowing scientists to make preciseii, repeatable powder rheology measurements simpler and faster. Such measurements enable materials scientists to optimize the processing and end-use performance of powders used in batteries, pharmaceuticals, additive manufacturing, food, personal care products, and coatings. Rheology is key to the understanding of materials in liquid, solid or powder form and how to turn them into high performance products. The TA Instruments HR Powder rheology accessory measures properties such as cohesion, stability, flowability energy and compressibility under industrially relevant processing conditions and to help laboratories: Screen battery electrode coatings, both solvent-based slurries and solvent-free dry coatings, to prevent defects and reduce cell failure rates Mix, granulate and compress solid-dose pharmaceutical tablets to prevent instabilities of API/excipient blends Optimize storage and transport of industrial powder materials and avoid supply chain disruptions. Annonce • Jul 13
Waters Corporation to Report Q2, 2022 Results on Aug 02, 2022 Waters Corporation announced that they will report Q2, 2022 results at 8:00 AM, US Eastern Standard Time on Aug 02, 2022 Annonce • Jun 26
Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index Annonce • Jun 07
Waters Corporation Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development Waters Corporation unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer. The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins, peptides and other biotherapeutics. Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts. New Software App for Confirming Nucleic Acid Sequence of Biotherapeutics. The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy. The CONFIRM Sequence app eliminates 50% of the time it takes for post-processing data review, accelerating characterization and development of nucleic acid therapeutics. The new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition, processing, and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice (GMP) labs. Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular Characterization. The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications. The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today, giving scientists a much clearer picture of the structure of their molecules at the isotope level. Annonce • May 05
Waters Corporation Provides Earnings Guidance for the Quarter Ending July 2, 2022 and Full Year Ending December 31, 2022 Waters Corporation provided earnings guidance for the quarter ending July 2, 2022 and full year ending December 31, 2022. For the quarter, the company constant currency sales growth in the range of 6% to 8%. Currency translation is expected to decrease second quarter sales growth by approximately four percentage points. GAAP earnings per diluted share to be between $2.52 to $2.62.For the year, the company constant currency sales growth in the range of 7.5% to 9%. Currency translation is expected to decrease full-year sales growth by approximately three percentage points. GAAP earnings per diluted share to be between $11.68 to $11.88. Annonce • Apr 15
Waters Corporation, Annual General Meeting, May 24, 2022 Waters Corporation, Annual General Meeting, May 24, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider To elect directors to serve for the ensuing year and until their successors are elected; to ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, by non-binding vote, executive compensation; and to consider and act upon any other matters which may properly come before the Annual Meeting or any adjournment thereof. Annonce • Apr 03
Waters Corporation Announces Resignation of John Ballbach from the Board of Directors On March 30, 2022, John Ballbach resigned from the Board of Directors (the “Board”) of Waters Corporation, effective as of such date. Mr. Ballbach has provided insightful strategic, operational and relevant industry perspective during his tenure. Annonce • Apr 01
Waters Introduces Xevo TQ Absolute Waters Corporation introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class. Waters’ newest high-performance mass spectrometer is up to 15X more sensitive for quantifying negatively ionizing compounds than its predecessorii and is 45% smaller and uses up to 50% less electricity and gas supply than other high-performance tandem quadrupole mass spectrometers available on the market.iii The Xevo TQ Absolute is designed to help pharmaceutical, food and beverage, and environmental analytical laboratories meet regulations requiring trace-level quantitative mass spectrometry analyses for a broad set of applications. Together, this integrated LC-MS/MS system is designed to drive the limits of quantitation to exceptionally low levels for many applications including: Quantifying regulated impurities in drug products. Performing oligonucleotide bioanalytical assays. Measuring concentrations of endogenous metabolites in large cohort clinical studies. Quantifying residues and contaminants in food and environmental samples. Measuring low-level drugs and toxicants in physiological matrices and Detecting trace-level leachables from food packaging. Annonce • Feb 02
Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 2, 2022 and Year Ending December 31, 2022 Waters Corporation provided earnings guidance for the first quarter ending April 2, 2022 and year ending December 31, 2022. For the quarter, the company expects constant currency sales growth in the range of 6% to 8%. Projected GAAP earnings per diluted share is expected to be in the range of $2.22 to $2.32. For the year, the company expects full-year 2022 constant currency sales growth in the range of 5% to 7%. Projected GAAP earnings per diluted share is expected to be in the range of $11.65 to $11.90. Annonce • Sep 15
Waters Corporation Introduces the Waters™ BioAccord™ System Waters Corporation introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with MaxPeak™ High Performance Surface (HPS) technology. The integrated high-resolution LC-MS system simplifies multi-attribute monitoring of biotherapeutics by improving analyte recovery and assay-to-assay reproducibility so that regulated laboratories can get needed medicines to patients faster. The compact, benchtop BioAccord System with ACQUITY Premier features MaxPeak HPS technology and the SmartMS™-enabled ACQUITY RDa™ mass detector allowing analysts of all abilities to monitor critical quality attributes of biotherapeutics and assess the processes that make them, all while decreasing risk, due to compliant-ready acquisition and data workflows that deliver consistent data quality from user-to-user and system-to-system. MaxPeak HPS technology is a hybrid organic/inorganic surface technology that forms a barrier between the sample and the biocompatible metal surfaces of both the UPLC inlet and column. By mitigating, or eliminating altogether, non-specific adsorption, MaxPeak HPS offers many benefits, among them: up to a 300% increase in detector sensitivity for more accurate glycan profiling, important for monitoring process and product quality of biologics; greatly improved analyte recovery and assay sensitivity for the measurement of modified peptides and impurities that are undetectable by conventional means; sharper peak shapes and greater peak capacity for more accurate analyte identification and data interpretation; greater reproducibility for separations prone to adsorptive losses meaning less re-work or troubleshooting, and more confidence in results; eliminates need for system passivation that wastes valuable sample material or ties up instrument cycles; eases the transfer of methods from site-to-site and from company-to-company. Annonce • Aug 05
Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2021 Waters Corporation provides earnings guidance for the third quarter and full year 2021. For the quarter, the company expects sales growth in the range of 8% to 10%. Projected GAAP earnings per diluted share to be in range of $2.22 to $2.32.
For the year, the company expects sales growth in the range of 14% to 17%. Projected GAAP earnings per diluted share to be in range of $10.60 to $10.80. Annonce • Jun 30
Waters Corporation Introduces TRIOS AutoPilot Software Waters Corporation introduced TRIOS AutoPilot software from its TA Instruments Division for its thermal analyzer product line. The software helps laboratory staff using TA’s thermal analyzers create routine and streamlined standard operating procedures (SOPs) up to 25% faster, and avoid transcription errors that can inhibit productivity and can lead to inconsistent thermal analysis measurements that are used to assess materials performance as well as batch-to-batch product quality. First-of-its-kind software for the TA Instruments thermal analysis product line, TRIOS AutoPilot software helps laboratory staff create routine and streamlined standard operating procedures (SOPs) up to 25% faster, and avoid
transcription errors that can inhibit productivity and can lead to inconsistent thermal analysis measurements. TRIOS AutoPilot is the first thermal analysis software to be based on Google’s visual programming interface, Blockly, which is opensource software that gives operators an intuitive way to create custom scripts and configure them for thermal analysis applications without the need to learn a higher-level programming language. Annonce • Jun 24
Waters Corp. Introduces the Waters Arc Premier System Waters Corp. announced that it has introduced the Waters Arc Premier System, calling it the first liquid chromatography system optimized for chromatographic separations on 2.5 - 3.5 micron columns to also feature Waters' novel MaxPeak High Performance Surface technology. The new system complements Waters' best-selling MaxPeak Premier Columns to virtually eliminate the surface interactions that occur between sample analytes and instrument and column hardware, saving laboratories time wasted on costly passivation and providing greater confidence in separations results. Analytical scientists working in method development and quality control laboratories can typically waste hours and days re-running or troubleshooting analytical methods that fail to reproduce an expected test result, such as missing low concentrations of a target analyte known to be in the sample or that fail to detect an impurity. MaxPeak HPS technology is a hybrid organic/inorganic surface technology exclusive to Waters' MaxPeak Premier Systems and Columns. It forms a barrier between the sample and the metal surfaces of both the system and column, mitigating, or eliminating altogether, non-specific adsorption. Annonce • May 26
Waters Corporation Introduces the Sars-Cov-2 Lc-Ms Kit (Ruo) to Advance Clinical Research of Infectious Diseases Waters Corporation introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results. Waters developed the SARS-CoV-2 LC-MS Kit (RUO) in support of a coalition of academic, commercial and government research scientists1. This coalition worked to develop an alternative test method on LC-MS platforms in support of the United Kingdom’s National Health Service (NHS) Test & Trace program. Their goal was to create a complementary, high-throughput screening method that would also use different reagents to help relieve strain on the PCR reagent supply chain. In just 16 weeks, the research coalition went from development of the method in university labs to a translated LC-MS workflow – upon which the SARS-CoV-2 LC-MS Kit (RUO) is based. Analytical tests show that researchers can achieve the analytical sensitivity required to detect and quantify low levels of three unique peptides derived from the SARS-CoV-2 NCAP protein – data on the Xevo™ TQ-XS System shows a lower limit of quantitation of just 3amol/µL. This is possible through the use of an innovative anti-peptide antibody enrichment sample preparation method and antibodies from SISCAPA® Assay Technologies that improves the performance of mass spectrometry for measurement of pre-selected protein targets. Results can be captured with clean, low-noise chromatograms in less than two minutes per sample. While further investigation is needed to collect objective evidence in promising research applications, initial test results and the readily adaptable properties of the analytical test method indicate the RUO kit could be leveraged for the following research studies:
Peptide concentration 2 – quantitate SARS-CoV-2 signature peptides at different stages of infection; Research of infection and long-term effects through peptide quantitation; and Future pandemic preparedness studies and research of signature peptide-based biomarkers may enable future research of other infections. Annonce • May 06
Waters Corporation Provides Earnings Guidance for the Three Months Ended July 3, 2021 and for the Full Year Ended December 31, 2021 Waters Corporation provided earnings guidance for the three months ended July 3, 2021 and for the full year ended December 31, 2021. For the three months, the company expects sales growth rate to be in range 16%-20%. Earnings per diluted share to be $2.10 to $2.20.
For the year, the company expects sales growth rate to be in range 9%-13%. Earnings per diluted share to be $9.65 to $9.85. Annonce • Mar 19
Waters Corporation Introduces A New Peptide Multi-Attribute Method Workflow for the Waters BioAccord LC-MS System Waters Corporation introduced a new peptide multi-attribute method (MAM) workflow for the Waters BioAccord LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs. The BioAccord System pairs the ACQUITY UPLC I-Class Plus with the ACQUITY RDa Mass Detector featuring SmartMS enabled usability features. The system offers a wide range of users with varying MS experience automated setup and self-diagnosis capability delivered through modern instrument control software and an intuitive user interface, all within a small footprint. In addition to peptide MAM, the BioAccord System also features workflows for other routine analyses of biotherapeutics: peptide mapping, intact/subunit mass analysis, released glycan profiling and oligonucleotide mass confirmation. waters_connect: A Single, Platform for LC and LC-MS Applications: waters_connect is a compliant-ready informatics platform enabling scientists to manage functionality of BioAccord System in workstation or laboratory networked deployments. It’s a growing platform of streamlined purpose-built applications that enhances the value that the BioAccord System brings to everyday sample analysis. Providing a complete audit trail for acquisition, processing and reporting of data, waters_connect meets and exceeds expectations for regulatory compliance, while maintaining the high standards of data integrity. Annonce • Mar 11
Waters Corporation Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector Waters Corporation released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight mass spectrometer for small molecule analysis for pharmaceutical, academic, food, and forensics applications. The accurate-mass ACQUITY™ RDa Detector can be quickly deployed and operated to enable faster and more informed decision-making across a broad set of applications. The ACQUITY RDa Detector featuring SmartMS technology is a time-of-flight mass detector for making accurate-mass measurements of small molecules during pharmaceutical impurity analyses, forced degradation studies, food and natural products analyses and seized drug profiling. From setup to results, the ACQUITY RDa Detector is designed for ease-of-use with intuitive system health checks and dedicated results-oriented workflows. With SmartMS, users can identify analytes more accurately and confidently evaluate outcomes with end-to-end robust, reliable workflows for routine applications. Paired with a simple one-button start, the RDa Detector reduces the extent of training, limits downtime, and ensures consistent, reproducible results. For improved usability and faster outcomes, the ACQUITY RDa Detector operates on waters_connect™, an open software platform designed to enhance the value that the RDa brings to laboratories with new functionality, features and software updates. Providing a complete audit trail for acquisition, processing and reporting of data, waters_connect enables seamless compliance and the highest standards of data integrity. With the option of system qualification, the platform is suitable for regulated and non-regulated laboratories alikeFeaturing an array of robust functionalities, simple operation, and a compact form factor, the ACQUITY RDa Detector simplifies the process of making high performance accurate- mass measurements. The ACQUITY RDa Detector is now available worldwide from Waters and its authorized distributors. Annonce • Feb 25
Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link Waters Corporation announced it has entered a reseller agreement with TetraScience. Through the partnership, Waters will now offer its customers the Empower™ Data Science Link, powered by TetraScience. This unique technology pairs Waters’, compliance-ready Empower Chromatography Data System (CDS) with TetraScience’s Data Platform and data science tools, providing unparalleled insights into chromatography data. Empower Data Science Link, powered by TetraScience is a cloud-native technology providing a solution for customers to unlock their Empower data and enable export into third party data analysis tools via standardized formats such as FAIR and Allotrope. Organizations can further accelerate scientific discovery by leveraging TetraScience’s cloud-native architecture, data science tools, and visualization capabilities. These features enable easier collection, normalization and centralization of data to help expedite development timelines and allow scientists to make better informed and earlier decisions. Annonce • Jan 29
Waters Corporation Introduces the OttoTM SPEcialist Positive Pressure Manifold Waters Corporation introduced the OttoTM SPEcialist Positive Pressure Manifold designed to improve the reliability and reproducibility of solid phase extraction (SPE). Equipped with easy-to-use, 21 CFR Part 11 compliant software and programmable pressure profiles, the Otto SPEcialist system provides confidence in SPE results by eliminating common workflow errors, reducing user variability, and documenting each method step to remove uncertainty and prevent duplicative efforts. By automating the various pressure applications of SPE, Otto helps laboratories achieve greater overall efficiency and is useful for a variety of pharmaceutical, biopharmaceutical food & beverage and environmental applications. For LC and LC-MS/MS analyses, sample preparation like SPE, is a necessary first step best automated to ensure reliability and reproducibility, especially when screening or analyzing significant numbers of samples and when consistency is important. Controlled with the intuitive, 21 CFR Part 11 compliant-ready Otto Software through an integrated tablet, Otto SPEcialist system enables the creation, editing, running, and sharing of pressure profiles and methods with little-to-no training. By utilizing positive pressure applied to the top of the device to control flow rather than vacuum processing applied to the bottom, Otto SPEcialist system offers more precise control for easier and more reliable sample processing. The system provides a wide pressure control range, accommodating a number of SPE device sizes and sorbent masses. The Otto SPEcialist system also creates contact with each individual cartridge or well, unlike vacuum processing where all cartridges or wells are connected to a single source. As compared to fully-automated SPE systems that are often complicated and costly to set up and run, the semi-automated Otto SPEcialist system – with easy-to-use software and a clean, simple interface – can be quickly deployed without significant capital investment. Users can create pressure profiles for every step of an SPE workflow – including load, wash and elution steps – at the push of a button. New and existing profiles, methods and processing parameters are tracked and documented, allowing for unfettered sharing across multiple days, users, laboratories, assays and Otto devices. This eliminates the variability associated with manual extraction procedures and ensures workflow consistency regardless of operator or environment. Otto SPEcialist system is compatible with a variety of sample plates, including Waters 96-well plates as well as larger 1 cc, 3 cc, and 6 cc cartridges, to easily scale methods as needed. Annonce • Jan 12
Waters Corporation's APGC-MS/MS System Accepted for Advanced Dioxin and Furan Analysis Following USEPA Approval of SGS AXYS Method 16130 Waters Corporation announced that its Xevo TQ-XS atmospheric pressure gas chromatography (APGC) mass spectrometry (MS) platform is an accepted alternative for the identification and quantification of dioxins and furans in environmental samples. Dioxins are a byproduct of human industrial activity and their effects on human health are well documented1. The acceptance of Method 16130 by the United States Environmental Protection Agency’s (USEPA) Office of Water comes after a review of validation data submitted by SGS AXYS Analytical Services Ltd. The USEPA’s acceptance of APGC-MS/MS comes after a two-year collaboration with SGS- AXYS. Analytical Services Ltd. Recognizing the need for a more efficient solution, Waters served as a key collaborator of SGS AXYS Analytical Services in the validation of APGC-MS/MS as an approved method for dioxin testing. The standard method, gas chromatography coupled with high-resolution magnetic sector mass spectrometry (GC-HRMS), is associated with large, aging, expensive instruments that are costly to run and maintain. Acceptance of the APGC-MS/MS method frees laboratories to deploy modern instrumentation that is less expensive, more sensitive and easier to operate. Annonce • Dec 11
Waters Corporation Appoints Pearl S. Huang to Board of Directors Waters Corporation announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021.
Dr. Huang is President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering. She currently serves on the boards of Cygnal Therapeutics and KSQ Therapeutics. She previously held senior roles
within the pharmaceutical industry, including Senior Vice President and Global Head of Therapeutic Modalities at Roche and Vice President and Global Head of Discovery Academic Partnerships at GSK. Annonce • Nov 19
Megadalton Solutions, Inc. Announces Expansion of Collaboration with Waters Corporation Megadalton Solutions Inc. announced the expansion of a collaboration with Waters Corporation to bring CDMS technology to a broader set of applications and potential customers in biopharma. The CDMS detector employed by Megadalton Solutions provides a high-throughput analytical tool for the cell and gene therapy sectors. Through their established agreement, Waters will conduct extensive testing of Megadalton's CDMS technology within its new Immerse Cambridge innovation and research lab, using it in collaborative engagements with academic and commercial pharma and biopharma partners in both the New England scientific community and beyond. Waters became a strategic investor in Megadalton Solutions in 2020. Large molecule mass spectrometry offers an important tool for the characterization and support of next-generation pharmaceutical biologics, which is a key component in Waters' customer experience initiatives. Annonce • Nov 05
Waters Corporation Gives More Laboratories Access to Mass Spectrometry with Rapid, Easy, and Compact RADIAN ASAP System Waters Corporation introduced the new RADIAN™ ASAP™ System, a novel direct mass detector engineered for non-mass spectrometry (MS) experts to conduct fast and accurate analyses of solids and liquids with minimal sample prep. The RADIAN ASAP System’s high-quality, simplified and rapid operation, compact design, and powerful software capabilities for real-time data visualization offers advantages and numerous test case scenarios for laboratories across a multitude of industries, including pharmaceuticals, forensics, food & beverage, chemicals & materials, and academia. Engineered using proven and robust single quadrupole MS technology, and combined with a dedicated Atmospheric Solids Analysis Probe (ASAP) source, the Waters™ RADIAN ASAP System achieves results in seconds after a sample is loaded into the system. Gaseous analyte molecules are ionized by N2 plasma, guided into the instrument and separated by their mass-to-charge ratio. Users obtain real-time sample classification and quality assessment in less than a minute, without the need for a chromatographic separation, conserving the time and resources traditionally lost to sample preparation. The RADIAN ASAP System is compatible with a variety of Waters software solutions, including OpenLynx, MassLynx™, IonLynx™ and LiveID™. Notably, Waters has released the latest iteration of its LiveID Software, LiveID 2.0, in conjunction with RADIAN ASAP. Offering an intuitive, modern interface and easy-to-interpret results, LiveID Software continues to offer model building capabilities for classifying samples and determining their authenticity. LiveID Software now also offers real-time spectral library-matching for identifying sample compounds by matching their spectra with reference library spectra stored in the software. The RADIAN ASAP System’s automated set-up, streamlined workflow, and easy operation with minimal training offers laboratories a flexible tool to meet rising demands without sacrificing on analytical performance. Notable applications include:
Pharmaceuticals, to provide easy access to mass spectral data for instantaneous assessment of reaction progress and the identification of purification fractions; Forensics, to empower the rapid, confident identification of illicit drugs against a library of known compounds; Food and Beverage, to improve food integrity by verifying product authenticity and safety, adulteration, or degradation by suppliers and regulators; Chemicals and Materials, to streamline quality control and product development workflows such as material release testing or formulation performance testing; and Academia, to supply academic laboratories with a robust and reliable solution for teaching and method development. Annonce • Oct 15
Waters Corporation Introduces Acquity Premier Columns Waters Corporation introduced ACQUITY PREMIER Columns, a new family of premium sub-2-micron columns featuring MaxPeak High Performance Surface (HPS) technology. The columns are for use with any brand of UHPLC system and can measurably improve data quality by mitigating the loss of sample analytes due to analyte-to-surface interactions. Designed for the analytical laboratory seeking to exercise greater control over their chromatographic separations, the columns improve sample throughput, assay-to-assay reproducibility and overall confidence in analytical results. Waters ACQUITY PREMIER Columns feature MaxPeak HPS technology, a hybrid organic/inorganic surface technology that forms a barrier surface layer between the sample and the stainless steel column. The benefits of this new technology are many, among them: increased sensitivity for low-level, metal-binding analytes that would otherwise go undetected and unseen; better all-around peak shapes and peak capacity for more accurate analyte identification and data interpretation; greater reproducibility for separations prone to adsorptive losses meaning less re-work or troubleshooting, and more confidence in results. 
